March 5, 2020 / 12:42 PM / 25 days ago

BRIEF-BioCryst Reports Q4 Loss Per Share $0.02

March 5 (Reuters) - BioCryst Pharmaceuticals Inc:

* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES

* Q4 REVENUE ESTIMATE $9.9 MILLION — REFINITIV IBES DATA

* Q4 EARNINGS PER SHARE ESTIMATE $-0.26 — REFINITIV IBES DATA

* EXPECTS FULL YEAR 2020 NET OPERATING CASH USE TO BE IN RANGE OF $125 TO $150 MILLION

* BIOCRYST PHARMACEUTICALS - EXPECTS FULL YEAR 2020 OPERATING EXPENSES TO BE IN RANGE OF $135 TO $160 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below